Evaluation of the effect of the specific CCR1 antagonist CP‐481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects
Jeanett Borregaard(Gentofte Hospital), Alan Clucas(Fondation Sophia Antipolis), Naitee Ting(Pfizer (United States)), Cunshan Wang(Pfizer (United States)), Lisa A. Beck(University of Rochester Medicine), Jesper Sonne(University of Copenhagen), Lisy Wang(Pfizer (United States)), Lone Skov(University of Copenhagen)
Cited by 13
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k